Actuate Therapeutics Net Income

Actuate Therapeutics (ACTU) currently reports a net income of $-20M as of June 2026. That compares with $-25M in the prior-year period — up 17.1% year over year. That is below the sector sector average of $96M. Use the charts on this page to explore Actuate Therapeutics's net income history and peer comparisons.

Actuate Therapeutics's net income increased from $-25M to $-20M — a 17.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Actuate Therapeutics's net income of $-20M is lower than the its sector sector average of $96M. That is roughly 121.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Actuate Therapeutics reported $-20M in net income as of June 2026. That compares with $-25M in the prior-year period — up 17.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-20M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $96M. From there, open related valuation or income-statement pages for Actuate Therapeutics, and consider following ACTU for alerts when major investors trade the stock.